for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sanofi India Ltd

SANO.NS

Latest Trade

5,890.20INR

Change

221.75(+3.91%)

Volume

34,767

Today's Range

5,642.00

 - 

5,984.00

52 Week Range

5,280.00

 - 

6,635.80

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
5,668.45
Open
5,675.00
Volume
34,767
3M AVG Volume
0.31
Today's High
5,984.00
Today's Low
5,642.00
52 Week High
6,635.80
52 Week Low
5,280.00
Shares Out (MIL)
23.00
Market Cap (MIL)
133,653.60
Forward P/E
31.22
Dividend (Yield %)
1.22

Next Event

Q3 2020 Sanofi India Ltd Earnings Release

Latest Developments

More

Sanofi India June-Quarter Profit Falls

Indian Pharma Firms Sent Notices By Govt Body For Introducing Drugs Without Approval

Sanofi India Dec-Qtr Profit Rises

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sanofi India Ltd

Sanofi India Limited is an India-based company, which is engaged in the manufacture and sale of pharmaceutical products. The Company provides medicines for the treatment of patients in various therapeutic areas, including cardiology, thrombosis, oncology, diabetes, central nervous system, internal medicine and consumer healthcare. The operations of the Company represent a primary business segment relating to pharmaceuticals. The Company has operations in India and Outside India. The Company has approximately two manufacturing facilities, including Ankleshwar, Gujarat (chemistry and pharmaceuticals) and Verna, Goa (pharmaceuticals). The Company's products include Cardace 10, Cardace am 5, Cardace H 5, Lasilactone 50, Combiflam Suspension, Augeoz, Caspercid, Zolineg, Zolineg 2, Combiflam Plus, Novalgin NU, Proctosedyl bd, Amino-fit, CoQ Forte, CoQ, FreeFlex Forte, FreeFlex, Folgel Plus, Icegel, Macraberin-M, Selace Forte, Seacod Capsule and Seacod Oil.

Industry

Biotechnology & Drugs

Contact Info

54/A

Sir Mathuradas Vasanji Road

Andheri East

+91.22.28032000

http://www.sanofiindialtd.com/

Executive Leadership

Aditya Narayan

Independent Non-Executive Chairman of the Board

Charles Billard

Chief Financial Officer, Whole time Director

Girish Tekchandani

Compliance Officer, Company Secretary

Rajaram Narayanan

Managing Director, Whole Time Director

Cherian Mathew

Additional and Whole Time Director

Key Stats

2.50 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2016

22.1K

2017

23.3K

2018

27.7K

2019(E)

29.8K
EPS (INR)

2016

129.130

2017

141.740

2018

165.480

2019(E)

185.871
Price To Earnings (TTM)
34.38
Price To Sales (TTM)
4.55
Price To Book (MRQ)
5.98
Price To Cash Flow (TTM)
27.12
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
16.99
Return on Equity (TTM)
13.36

Latest News

BRIEF-Sanofi India Seeks Shareholders' Nod To Appoint Rajaram Narayanan As MD

* SEEKS SHAREHOLDERS' NOD FOR APPOINTMENT OF RAJARAM NARAYANAN AS MD Source text - http://bit.ly/2qlh9aK Further company coverage:

BRIEF-Sanofi India Dec Qtr Profit Rises

* DEC QTR TOTAL REVENUE FROM OPS 6.70 BLN RUPEES VS 6.05 BLN RUPEES YR AGO Source text - http://bit.ly/2EYEvwc Further company coverage:

BRIEF-Sanofi Launches New Insulin Toujeo In India

* LAUNCHES NEW INSULIN TOUJEOTM IN INDIA Source text - http://bit.ly/2H7ZlXX Further company coverage:

BRIEF-Sanofi India Appoints Rajaram Narayanan As MD

* SAYS RAJARAM NARAYANAN APPOINTED AS MD Source text: http://bit.ly/2ku88co Further company coverage:

BRIEF-Sanofi India Sept-qtr profit up 40 pct

* Sept quarter total revenue from operations 6.68 billion rupees

BRIEF-Sanofi India launches Combiflam ICYHOT pain relief topical in India

* Says Sanofi launches Combiflam ICYHOT pain relief topical in India Source text for Eikon: Further company coverage:

BRIEF-Sanofi India seeks members' nod for increasing loan to 4.45 bln rupees to Shantha Biotechnics

* Seeks members' nod for increasing loan from INR 3.30 billion to INR 4.45 billion to Shantha Biotechnics Pvt Ltd Source text - http://bit.ly/2vHzQqW Further company coverage:

BRIEF-Sanofi India declares interim dividend of 18 rupees per share

* Says declared an interim dividend of INR 18 per equity share Source text - (http://bit.ly/2viW1nc) Further company coverage:

BRIEF-Sanofi India June-qtr profit down 14.4 pct

* June quarter total revenue from operations 6.01 billion rupees

BRIEF-Sanofi India March qtr profit down about 27 pct

* Net profit in march quarter last year was 826 million rupees as per Ind-AS; total income was 5.82 billion rupees Source text - (http://bit.ly/2qH8L4x) Further company coverage:

BRIEF-Sanofi India says news on FDA approval for eczema drug not related to co

* Clarifies on news item "FDA approves Regeneron, Sanofi $37,000 per year eczema drug"

BRIEF-Sanofi India Dec-qtr profit falls about 58 pct

* Net profit in Dec quarter last year was 1.20 billion rupees; net sales was 5.22 billion rupees

BRIEF-Sanofi India Sept-qtr profit up about 11 pct

* Net profit in sept quarter last year was 725 million rupees; net sales was 5.53 billion rupees Source text: http://bit.ly/2eF0GcN Further company coverage: (Bengaluru newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up